All 1 tracked stories fall under one category: pharma. Courtney Miller is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each carries 2 original sources on average. We currently track 1 Biotech story that mention BioFlorida, all published on March 10, 2026.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about BioFlorida
All 1 tracked stories fall under one category: pharma. Courtney Miller is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each carries 2 original sources on average. We currently track 1 Biotech story that mention BioFlorida, all published on March 10, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 19 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering BioFlorida. Shared-story counts are live from our verified record — not editorial picks.
Myosin Therapeutics is set to present its first-in-class NMIIA/IIB inhibitor, MT-125, at two major South Florida life sciences conferences this March. The company's unique approach targets the physical mechanics of glioblastoma cells, offering a potential solution to traditional drug resistance.
BioFlorida is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source
link? Report a data issue.